https://vsv-eboplus.eu/systems-analysis-of-adult-and-pediatric-responses-to-the-vsv-zebov-ebola-vaccine/2019-12-04T14:26:17+01:00https://vsv-eboplus.eu/lotta-allebola-nasce-un-nuovo-progetto-di-ricerca-sulla-risposta-dei-vaccini/2019-12-04T14:26:17+01:00https://vsv-eboplus.eu/ny-europeisk-mangmiljonsatsning-pa-ebolavaccin/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/grote-subsidie-voor-het-testen-van-ebola-vaccin/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/lumc-krijgt-17-miljoen-euro-voor-onderzoek-ebola-medicijn/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/lumc-krijgt-17-miljoen-voor-testen-ebola-vaccin/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/tropenmedizin-an-kooperationsprojekt-zur-erforschung-eines-ebola-impfstoffes-beteiligt/2019-12-04T16:30:33+01:00https://vsv-eboplus.eu/ebola-university-of-siena-launches-major-research-project/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/ebola-progetto-da-oltre-15-mln-su-vaccino-siena-in-prima-linea/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/ebola-university-of-siena-in-the-forefront-of-international-research-for-a-vaccine/2019-12-04T14:25:51+01:00https://vsv-eboplus.eu/siena-al-centro-di-un-nuovo-progetto-per-contrastare-lebola/2019-12-04T14:25:48+01:00https://vsv-eboplus.eu/lotta-allebola-siena-nel-progetto-di-ricerca/2019-12-04T14:25:48+01:00https://vsv-eboplus.eu/ebola-progetto-da-oltre-15-milioni-per-il-vaccino-siena-in-prima-linea/2019-12-04T14:25:47+01:00https://vsv-eboplus.eu/ebola-progetto-da-oltre-15-mln-su-vaccino-siena-in-prima-linea-2/2019-12-04T14:25:47+01:00https://vsv-eboplus.eu/ebola-luniversita-fa-ricerca/2019-12-04T14:25:47+01:00https://vsv-eboplus.eu/vaccino-per-lebola-siena-in-prima-linea-partito-il-progetto-europeo-da-15-mln-di-euro/2019-12-06T11:41:46+01:00https://vsv-eboplus.eu/10-phd-student-positions-msca/2023-01-21T11:23:21+01:00https://vsv-eboplus.eu/first-vaccine-to-protect-against-ebola/2023-01-21T11:22:41+01:00https://vsv-eboplus.eu/vaccine-against-ebola-commission-grants-first-ever-market-authorisation/2023-01-21T11:22:56+01:00https://vsv-eboplus.eu/who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries/2023-01-21T11:22:29+01:00https://vsv-eboplus.eu/siena-lotta-allebola-al-via-un-grande-progetto-di-ricerca-sullo-studio-della-risposta-al-vaccino-vsv-zebov/2019-12-04T14:25:02+01:00https://vsv-eboplus.eu/tutti-i-vaccini-del-terzo-millennio/2023-01-21T11:23:08+01:00https://vsv-eboplus.eu/first-fda-approved-vaccine-for-the-prevention-of-ebola-virus-disease-marking-a-critical-milestone-in-public-health-preparedness-and-response/2023-01-21T11:22:18+01:00https://vsv-eboplus.eu/virtual-meeting-of-the-vsv-eboplus-project/2023-03-25T11:04:01+01:00https://vsv-eboplus.eu/helder-nakaya-highly-cited-researcher-2020/2023-01-21T11:21:47+01:00https://vsv-eboplus.eu/virtual-meeting-of-the-vsv-eboplus-project-2/2023-01-21T11:21:59+01:00https://vsv-eboplus.eu/unicef-who-ifrc-and-msf-announce-the-establishment-of-a-global-ebola-vaccine-stockpile/2023-01-21T11:21:33+01:00https://vsv-eboplus.eu/new-ebola-outbreak-declared-in-guinea/2023-01-21T11:21:19+01:00https://vsv-eboplus.eu/vsv-eboplus-annual-meeting-2021/2023-01-21T11:21:06+01:00https://vsv-eboplus.eu/vsv-eboplus-annual-meeting-2022/2023-03-21T14:16:31+01:00https://vsv-eboplus.eu/vsv-eboplus-final-meeting-2023/2023-07-19T13:24:24+02:00https://vsv-eboplus.eu/vsv-eboplus-conference/2023-07-20T10:09:11+02:00https://vsv-eboplus.eu/vsv-eboplus-project-results-presented-at-open-conference-28-march-2023/2023-07-20T10:08:28+02:00https://vsv-eboplus.eu/vsv-eboplus-project-organized-its-final-meeting-on-27-29-march-2023/2023-07-19T16:25:42+02:00https://vsv-eboplus.eu/the-24th-international-pathogenic-neisseria-conference-ipnc-will-take-place-in-florence-italy-from-the-31st-march-to-the-4th-april-2025/2024-11-11T22:15:35+01:00